ImmunityBio Shares Surge as Short Sellers Face Mounting Pressure

ImmunityBio US45256X1037

The biotech sector is witnessing a remarkable event as ImmunityBio experiences a parabolic rally to begin the year. This surge has caught bearish investors off guard, propelling the stock to unprecedented levels. While speculative forces are at play, the movement is also underpinned by concrete regulatory developments and clinical data. The critical question for the market is determining what portion of this ascent is driven by fundamental progress versus a classic short squeeze.

Beyond the dramatic price action, ImmunityBio has reported several key operational advancements that contribute to the bullish sentiment:

• International Regulatory Success: The Saudi Food and Drug Authority (SFDA) has granted approval for ANKTIVA Read more...